Customers are looking for solutions that have clear evidence supporting its clinical performance and compatibility with their existing IT and equipment infrastructures.
VIENNA (PRWEB) February 28, 2019
At ECR 2019 in Vienna, ScreenPoint Medical will present the latest version of Transpara™ Artificial Intelligence (AI) system, which processes 2D, 3D and combo mammography exams and is integrated in the workstations of an increasing number of OEM partners.
ScreenPoint Medical’s Transpara™ is the first AI application for detecting breast cancer in screening mammograms to gain 510(k) clearance from the FDA, based on its unique functionality which interactively provides support for detection and diagnosis. The clearance was supported by the results of a multi-reader, multi-case Reader Study, which demonstrated that radiologists significantly improved detection accuracy when using Transpara for decision support without increasing reading times.
"This year's exhibit shows our commitment to the changing AI landscape," said Nico Karssemeijer, CEO for ScreenPoint Medical. "Customers are looking for solutions that have clear evidence supporting its clinical performance and compatibility with their existing IT and equipment infrastructures. Our development team has worked hard to ensure this a real possibility."
These commercially available 2D, 3D and combo mammography solutions are on display at the Annual ECR meeting in Vienna, Austria this week. ScreenPoint Medical was also recently selected by an expert panel as the best new Radiology Vendor in the EuroMinnie Awards 2019.
Clinical Studies to watch out for at ECR 2019:
According to the study, “Can artificial intelligence identify normal mammograms in screening?” (B-0695, February 28, 14:09, Room: E1), presented by K. Lång (Malmo, Sweden), at ECR 2019, an artificial intelligence system can reduce the screen-reading workload and with further improvement of the software, an even greater exclusion of normal mammograms seems possible, since the majority of the cancers with low risk scores were clearly visible.
In the session “Artificial intelligence detecting breast cancer on mammography: does breast density play a role?” (B-0697, February 28, 14:25, Room: E1), a study will be presented by A. Rodriguez Ruiz. Researchers from Radboud University Medical Centre in Nijmegen, Netherlands concluded that the AI score may be considered as an independent tool to estimate the likelihood of the presence of cancer on mammograms, to stratify screening populations, and to potentially speed up the reading process by reassuring readers on mammograms that are likely normal, irrespective of breast density.
About ScreenPoint Medical BV:
ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence.
ScreenPoint Medical was founded in 2014 by Nico Karssemeijer and Michael Brady, two experts in breast imaging, machine learning, computer vision, and computer-aided detection. The main office is in Nijmegen, The Netherlands. For more information, please contact info(at)screenpointmed.com